ANI Pharmaceuticals Q4 2022 Earnings Report
Key Takeaways
ANI Pharmaceuticals reported Q4 net revenues of $94.2 million, a net loss available to common shareholders of $(4.7) million, and an adjusted non-GAAP diluted earnings per share of $0.76. The company's full-year 2022 net revenues reached $316.4 million.
Q4 net revenues reached $94.2 million, marking a 54.7% growth.
Adjusted non-GAAP diluted earnings per share for Q4 was $0.76.
Full year 2022 net revenues were $316.4 million.
Purified Cortrophin Gel full-year 2022 net sales reached $41.7 million.
ANI Pharmaceuticals
ANI Pharmaceuticals
ANI Pharmaceuticals Revenue by Segment
Forward Guidance
ANI Pharmaceuticals initiates total Company net revenue guidance of $360 million to $385 million; adjusted non-GAAP EBITDA guidance of $78 million to $88 million; adjusted non-GAAP earnings per share of $2.09 to $2.59.
Positive Outlook
- Total Company expected Net Revenues between $360.0 million and $385.0 million, representing approximately 14% to 22% growth as compared to $316.4 million recognized in 2022
- Cortrophin specific revenue guidance between $80.0 million to $90.0 million, representing 92% to 116% growth as compared to $41.7 million recognized in 2022
- Total Company non-GAAP Gross Margin between 59.5% and 61.0%
- Total Company Adjusted non-GAAP EBITDA between $78.0 million and $88.0 million
- Adjusted non-GAAP Diluted Earnings per Share between $2.09 and $2.59
Revenue & Expenses
Visualization of income flow from segment revenue to net income